AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications. AbRegen owns a broad intellectual property portfolio related to the modulation of Flightless I, a key regulator of cell growth and migration. The t...See more
Headquarter Australia |
Countries of operation Australia |
Funding status Private |
Company type SME |